Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.

ABSTRACT:

Background

Anti-CD47 monoclonal antibodies have increasing clinical applications in the treatment of cancer. However, anti-CD47 monoclonal antibodies interfere with immunohematology testing in patients who require blood transfusion. As the current approaches to removing any interferences have technical problems, new methods need to be developed to resolve anti-CD47 interference in immunohematology testing.

Materials and methods

We evaluated the Daudi cell line for the adsorption of free anti-CD47 monoclonal antibodies from patients' plasma to facilitate immunohematology testing in patients treated with anti-CD47 monoclonal antibody. CD47 expression was identified on the Daudi cells using flow cytometry and confocal microscopy. Next, we tested the ability of intact Daudi cell

SUBMITTER: Wei H 

PROVIDER: S-EPMC10812897 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature